Plexxikon, Roche Opening EAP
PLX4032 Shines in Phase II; Possible Early Approval?
By Jennifer Boggs
Monday, November 8, 2010
Plexxikon Inc.'s and Roche AG's melanoma drug PLX4032 (RG7204) continued its streak of stellar data, with results from an open-label Phase II trial showing a 52 percent response rate in patients with previously treated disease with the BRAF V600E mutation, and the companies are planning to open an access program to answer growing patient demand for the drug ahead of approval. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.